Iman El‐Hariry

3.7k total citations · 1 hit paper
56 papers, 2.5k citations indexed

About

Iman El‐Hariry is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Iman El‐Hariry has authored 56 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 20 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Iman El‐Hariry's work include Lung Cancer Treatments and Mutations (12 papers), Heat shock proteins research (12 papers) and Head and Neck Cancer Studies (10 papers). Iman El‐Hariry is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Heat shock proteins research (12 papers) and Head and Neck Cancer Studies (10 papers). Iman El‐Hariry collaborates with scholars based in United Kingdom, United States and France. Iman El‐Hariry's co-authors include Hisham Mehanna, Sally Roberts, Vinidh Paleri, Christopher C. McConkey, T. Nicholson, Massimo Pignatelli, Anastasios J. Karayiannakis, W A Kmiot, Kevin J. Harrington and Alireza Valizadeh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Iman El‐Hariry

56 papers receiving 2.5k citations

Hit Papers

Prevalence of human papillomavirus in oropharyngeal and n... 2012 2026 2016 2021 2012 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region
    2012 624 citations Hisham Mehanna, Iman El‐Hariry et al. Head & Neck profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iman El‐Hariry United Kingdom 22 966 865 843 739 661 56 2.5k
Sang‐Hue Yen Taiwan 23 390 0.4× 512 0.6× 194 0.2× 315 0.4× 352 0.5× 52 1.8k
Ingrid Hofland Netherlands 19 830 0.9× 863 1.0× 168 0.2× 486 0.7× 220 0.3× 36 2.1k
Caroline Even France 22 332 0.3× 1.8k 2.0× 853 1.0× 812 1.1× 692 1.0× 142 2.5k
Mark Sydenham United Kingdom 16 435 0.5× 877 1.0× 1.1k 1.3× 937 1.3× 823 1.2× 42 3.3k
Sacha I. Rothschild Switzerland 29 845 0.9× 1.4k 1.7× 123 0.1× 839 1.1× 262 0.4× 128 2.6k
Jean‐Pascal Machiels Belgium 23 461 0.5× 808 0.9× 251 0.3× 290 0.4× 286 0.4× 58 1.6k
J Maestre Spain 14 706 0.7× 1.1k 1.2× 81 0.1× 1.6k 2.2× 382 0.6× 26 2.5k
Ammar Sukari United States 24 640 0.7× 1.5k 1.8× 372 0.4× 635 0.9× 311 0.5× 118 2.3k
Shahnaz Begum United States 35 2.2k 2.3× 1.6k 1.8× 2.1k 2.5× 670 0.9× 1.6k 2.4× 51 5.0k
Mitsuo Ohta Japan 26 318 0.3× 1.2k 1.4× 85 0.1× 1.6k 2.2× 370 0.6× 86 2.5k

Countries citing papers authored by Iman El‐Hariry

Since Specialization
Citations

This map shows the geographic impact of Iman El‐Hariry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iman El‐Hariry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iman El‐Hariry more than expected).

Fields of papers citing papers by Iman El‐Hariry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iman El‐Hariry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iman El‐Hariry. The network helps show where Iman El‐Hariry may publish in the future.

Co-authorship network of co-authors of Iman El‐Hariry

This figure shows the co-authorship network connecting the top 25 collaborators of Iman El‐Hariry. A scholar is included among the top collaborators of Iman El‐Hariry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iman El‐Hariry. Iman El‐Hariry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hammel, Pascal, Laurent Mineur, J-P. Metges, et al.. (2017). A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180). Annals of Oncology. 28. v211–v211. 8 indexed citations
2.
Lorenzi, Philip L., Thomas D. Horvath, Wai Kin Chan, et al.. (2016). Red Blood Cell-Encapsulation of L-Asparaginase Favorably Modulates Target Selectivity and Pharmacodynamics. Blood. 128(22). 1266–1266. 3 indexed citations
3.
Shatzer, Amber N., Mir A. Ali, Kennichi Dowdell, et al.. (2016). Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood. Leukemia & lymphoma. 58(4). 923–931. 15 indexed citations
4.
Mehanna, Hisham, Natalie Compton, Max Robinson, et al.. (2016). Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials. Head & Neck. 38(S1). E1863–9. 42 indexed citations
5.
Proia, David A., Chaohua Zhang, Manuel Sequeira, et al.. (2013). Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer. Clinical Cancer Research. 20(2). 413–424. 53 indexed citations
6.
Sang, Jim, Jaime Acquaviva, Julie C. Friedland, et al.. (2013). Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Cancer Discovery. 3(4). 430–443. 174 indexed citations
7.
Nagaraju, Ganji Purnachandra, Wungki Park, Jing Wen, et al.. (2013). Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis. 16(4). 903–917. 71 indexed citations
8.
9.
10.
Campo, J.M. del, Ricardo Hitt, P. Sebastian, et al.. (2011). Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. British Journal of Cancer. 105(5). 618–627. 89 indexed citations
11.
Landis, Sarah, Iman El‐Hariry, Myrthe P. P. van Herk‐Sukel, et al.. (2011). Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. Head & Neck. 34(2). 238–244. 25 indexed citations
12.
Bhide, Shreerang, Mark Davies, Kevin Burke, et al.. (2010). Weekly Volume and Dosimetric Changes During Chemoradiotherapy With Intensity-Modulated Radiation Therapy for Head and Neck Cancer: A Prospective Observational Study. International Journal of Radiation Oncology*Biology*Physics. 76(5). 1360–1368. 181 indexed citations
13.
El‐Hariry, Iman, Thomas Powles, Mike Lau, et al.. (2010). Amplification of epidermal growth factor receptor gene in renal cell carcinoma. European Journal of Cancer. 46(5). 859–862. 8 indexed citations
14.
Harrington, Kevin J., Iman El‐Hariry, Antoine Lusinchi, et al.. (2009). Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 27(7). 1100–1107. 52 indexed citations
15.
Wülfing, Christian, J-P. Machiels, Dick J. Richel, et al.. (2005). A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Journal of Clinical Oncology. 23(16_suppl). 4594–4594. 43 indexed citations
16.
El‐Hariry, Iman, Massimo Pignatelli, & Nicholas R. Lemoine. (2001). FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. International Journal of Cancer. 94(5). 652–661. 32 indexed citations
17.
Llovet, Josep M., Paul Ruff, Nikos Tassopoulos, et al.. (2001). A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. European Journal of Cancer. 37(11). 1352–1358. 18 indexed citations
18.
19.
El‐Hariry, Iman, et al.. (1999). Characterization of the E-cadherin-catenin complexes in pancreatic carcinoma cell lines. The Journal of Pathology. 188(2). 155–162. 13 indexed citations
20.
El‐Hariry, Iman & Massimo Pignatelli. (1997). Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer. Expert Opinion on Investigational Drugs. 6(10). 1465–1478. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sang‐Hue Yen Breakdown of academic impact, for papers by Ingrid Hofland Breakdown of academic impact, for papers by Caroline Even Breakdown of academic impact, for papers by Mark Sydenham Breakdown of academic impact, for papers by Sacha I. Rothschild Breakdown of academic impact, for papers by Jean‐Pascal Machiels Breakdown of academic impact, for papers by J Maestre Breakdown of academic impact, for papers by Ammar Sukari Breakdown of academic impact, for papers by Shahnaz Begum Breakdown of academic impact, for papers by Mitsuo Ohta
Rankless by CCL
2026